Bivalirudin Versus Heparin Plus Glycoprotein IIb/IIIa Inhibitors in Patients with Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
Uzoma N IbebuoguGuy L Reed

Abstract

Diabetes mellitus (DM) is a pro-thrombotic state with enhanced thrombin generation and platelet reactivity. For most patients undergoing percutaneous coronary intervention (PCI), bivalirudin demonstrates efficacy comparable with that of heparin and glycoprotein IIb/IIIa inhibitors (GPIs). Yet, because of their pro-thrombotic condition, we hypothesized that patients with DM may benefit from more aggressive dual antithrombin and antiplatelet therapy. The aim of this paper was to provide a systematic review comparing outcomes of PCI with bivalirudin versus heparin plus GPI in patients with DM using meta-analytical techniques. Eligible studies needed to have reported a subgroup analysis of outcomes among diabetic patients. Six trials comprising 5924 diabetic patients were eligible. At 30 days, bivalirudin was associated with a reduction in net adverse cardiac events [relative risk (RR) 0.81, 95 % confidence interval (CI) 0.70-0.93, p = 0.002] and major bleeds (RR 0.68, 95 % CI 0.49-0.95; p = 0.02), with no difference in composite ischemia (RR 0.92, 95 % CI 0.74-1.14; p = 0.43) or mortality (RR 0.71, 95 % CI 0.45-1.13; p = 0.15). At 1 year, bivalirudin was associated with a significant reduction in all-cause mortality (RR 0.73, 95 %...Continue Reading

References

Jan 1, 1990·Annual Review of Cell Biology·D D Wagner
Nov 1, 1987·The American Journal of Cardiology·G F LempJ M Sullivan
Jun 10, 1993·The New England Journal of Medicine·D M Nathan
Aug 11, 2000·JAMA : the Journal of the American Medical Association·E M AntmanE Braunwald
Jul 27, 2001·Diabetes Care·A I VinikG L Pittenger
Jan 15, 2002·Arteriosclerosis, Thrombosis, and Vascular Biology·Jukka WesterbackaRiitta Lassila
Sep 13, 2002·Journal of the American College of Cardiology·Tauqir Y GorayaVéronique L Roger
Apr 20, 2004·Journal of the American College of Cardiology·Roxana MehranMartin B Leon
Mar 24, 2005·JAMA : the Journal of the American Medical Association·James D Flaherty, Charles J Davidson
Nov 25, 2006·The New England Journal of Medicine·Gregg W StoneUNKNOWN ACUITY Investigators
May 24, 2008·The New England Journal of Medicine·Gregg W StoneUNKNOWN HORIZONS-AMI Trial Investigators
Aug 16, 2008·The New England Journal of Medicine·Adnan KastratiUNKNOWN ISAR-REACT 3 Trial Investigators
Nov 22, 2008·Journal of the American College of Cardiology·Duane S PintoUNKNOWN ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Investigators
Nov 15, 2011·The New England Journal of Medicine·Adnan KastratiUNKNOWN ISAR-REACT 4 Trial Investigators
Nov 1, 2013·The New England Journal of Medicine·Philippe Gabriel StegUNKNOWN EUROMAX Investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.